Medipattern B-CAD(TM) to be Made Available in Canada

The Medipattern Corporation (CDNX: - ), an award-winningdeveloper of computer-aided detection (CAD) medical imagingsoftware designed to aid physicians in making better informedbiopsy decisions and to permit a higher standard of carefor the millions of patients at risk of breast cancer, ispleased to announce an agreement with Osiris Medical Inc.(Osiris) for distribution of B-CAD in Canada.

Osiris is a distributor of high-quality diagnostic ultrasoundimaging systems in the radiology, cardiology, and surgicalmarkets. Osiris' network of regionally focused sales andapplications professionals offer customer support at a locallevel across Canada. Osiris is the exclusive Canadian distributorfor Siemens Worldwide Ultrasound Group. Its employees arewell-versed in all aspects of the ultrasound business andtheir skills bring more than 160 years of combined knowledgeto the "Canadian" health care market.

"With our long-term partnership with Siemens Acuson Ultrasound,we provide a one-stop solution for the very best in high-qualitypremium digital imaging systems and accessories. We seeB-CAD as a natural fit to the business we conduct acrossCanada", said Nick Hoffmann, President of Osiris MedicalInc. "Medipattern's software provides useful clinical informationand seamless integration into ultrasound systems, culminatingin a detailed report that captures all the relevant informationfor patient treatment or follow-up."

"Nick and the team at Osiris provide Medipattern with anexceptional knowledge of the Canadian healthcare marketand in particular the ultrasound market. Their focus anddedication to the sales, service, and support of ultrasoundis a natural fit for our B-CAD product," commented JeffCollins, CEO of The Medipattern Corporation. "We welcomeOsiris to our growing family of resellers worldwide andlook forward to working with them on the integration ofB-CAD into their extensive network of customers across Canada."

Upcoming Events:

Medipattern will participate in the following events:

- Radiological Society of North America (RSNA) booth 5515,November 25 to 29, 2007, Chicago, IL.

- European Congress of Radiology, March 7 to 11, Vienna,Austria

The Medipattern Corporation

Medipattern develops computer-aided detection (CAD) solutionsfor medical imaging. These products enhance workflow whileimproving interpretive and diagnostic confidence. The Company'sinitial clinical applications are B-CAD(TM) for breast ultrasoundand B-CADMRI(TM). Both have received awards for innovationin the industry. The B-CAD products use pattern recognitiontechnology to assist radiologists in their efforts to classifyand characterize lesions in images of the breast. Medipatternwas founded to design software products that detect andidentify lesions in breast imaging to support a higher standardof medical care. Please visit the company's website at:.

B-CAD(TM) and B-CADMRI(TM) are trademarks of The MedipatternCorporation.

Medipattern® is a registered mark of The MedipatternCorporation. BI-RADS® is a registered trademark ofthe American College of Radiology.

Forward-looking statements

This document contains forward-looking statements relatingto Medipattern's performance, operations, or business environment.These statements are based on what we believe are reasonableassumptions given currently available information and ourunderstanding of Medipattern's current activities. We havetried, whenever possible, to identify these forward-lookingstatements using words such as "anticipates", "believes","estimates", "expects", "plans", "intends", "potential",and similar expressions. Forward-looking statements arenot guarantees of future performance and involve risks anduncertainties that are difficult to predict or control.A number of factors could cause actual outcomes and resultsto differ materially from those expressed in forward-lookingstatements. These factors include but are not limited tothose set forth in the Company's corporate filings, (postedat ). Inaddition, these forward-looking statements relate to thedate on which they are made. The Company disclaims any intentionor obligation to update or revise any forward-looking statementsfor any reason. Readers should not rely on forward-lookingstatements.

The TSX Venture Exchange does not accept responsibilityfor the adequacy or accuracy of this release and has neitherapproved nor disapproved of the contents of this release.